-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Jim Bartel Named Chief Executive Officer of Vantage MedTech
Jim Bartel Named Chief Executive Officer of Vantage MedTech
LENEXA, Kan. and MOONACHIE, N.J., April 23, 2024 /PRNewswire/ -- Vantage MedTech ("Vantage"), a leading provider of comprehensive design and manufacturing services for medical technology innovations, is pleased to announce the appointment of Jim Bartel as Chief Executive Officer.
Mr. Bartel brings over 25 years of leadership experience within medical device and contract manufacturing organizations, including roles leading marketing, business development, and sales teams. With a passion for services and manufacturing, Mr. Bartel has a deep understanding of product development and building high-performing teams that share common values to accelerate growth.
He most recently served as CEO and Board Member of Waltek, Inc., a private equity-owned casting and machining company serving the medical industry, and President of Spectralytics, Inc., a medical device contract manufacturing organization, in addition to being COO and Board Member of Precision ADM, a 3D metal contract manufacturing company. He also spent four years at Stratasys, the leading 3D printing company, as VP and General Manager of their rapid prototyping business unit. Mr. Bartel holds a B.A., dual majors, in Economics and Management from Hartwick College and an M.B.A., focused on Business, Management, and Marketing, from the University of St. Thomas, Opus College of Business.
Upon his appointment as CEO, Mr. Bartel commented, "Vantage has been on an exciting growth journey, and I'm grateful for the opportunity to serve as CEO. We have a talented team of 150+ medical device engineers with decades of industry expertise. Their dedication to partnering with medical device innovators from concept to realization is what makes Vantage stand apart and is key to our long term success."
Vantage is backed by Boston-based private equity firm Ampersand Capital Partners ("Ampersand"). Trevor Wahlbrink, Partner at Ampersand added "We are thrilled to have Jim join the Vantage team given his exceptional leadership qualities and deep understanding of contract services companies serving the medical device industry. His experience, commitment to quality, and teamwork mentality will prove invaluable to Vantage's growth strategy."
About Vantage MedTech
Vantage MedTech provides comprehensive design and manufacturing services, supporting the advancement of medical technologies from concept through to product realization. Partnering with the world's most innovative MedTech start-ups and large medical device companies, we offer feasibility support, product development and prototyping, clinical and commercial manufacturing, and after-market services to support every phase of the product life cycle. Our clients can leverage our proprietary Advantage Platforms, accelerating product development timelines. Our manufacturing approach is structured to serve the changing needs of our clients, supporting small-quantity clinical or First-in-Human builds and can scale to accommodate full launch quantities. Vantage MedTech has facilities in Moonachie, New Jersey and Lenexa, Kansas. Additional information is available at available at VantageMedTech.com and on LinkedIn.
About Ampersand Capital Partners
Founded in 1988, Ampersand Capital Partners is a middle market private equity firm with $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit Ampersandcapital.com or follow us on LinkedIn.
Contact:
Emily Shores
913-385-5700
[email protected]
SOURCE Vantage MedTech
LENEXA, Kan. and MOONACHIE, N.J., April 23, 2024 /PRNewswire/ -- Vantage MedTech ("Vantage"), a leading provider of comprehensive design and manufacturing services for medical technology innovations, is pleased to announce the appointment of Jim Bartel as Chief Executive Officer.
堪萨斯州莱内克萨和新泽西州穆纳奇,2024年4月23日 /PRNewswire/ — 医疗技术创新综合设计和制造服务的领先提供商Vantage MedTech(“Vantage”)很高兴地宣布任命吉姆·巴特尔为首席执行官。
Mr. Bartel brings over 25 years of leadership experience within medical device and contract manufacturing organizations, including roles leading marketing, business development, and sales teams. With a passion for services and manufacturing, Mr. Bartel has a deep understanding of product development and building high-performing teams that share common values to accelerate growth.
Bartel 先生在医疗器械和合同制造组织中拥有超过 25 年的领导经验,包括领导营销、业务开发和销售团队。Bartel 先生对服务和制造业充满热情,对产品开发和建立具有共同价值观的高绩效团队有着深刻的理解,以加速增长。
He most recently served as CEO and Board Member of Waltek, Inc., a private equity-owned casting and machining company serving the medical industry, and President of Spectralytics, Inc., a medical device contract manufacturing organization, in addition to being COO and Board Member of Precision ADM, a 3D metal contract manufacturing company. He also spent four years at Stratasys, the leading 3D printing company, as VP and General Manager of their rapid prototyping business unit. Mr. Bartel holds a B.A., dual majors, in Economics and Management from Hartwick College and an M.B.A., focused on Business, Management, and Marketing, from the University of St. Thomas, Opus College of Business.
除了担任三维金属合约制造公司Precision ADM的首席运营官兼董事会成员外,他最近还担任过Waltek, Inc.(一家为医疗行业服务的私募股权铸造和加工公司)的首席执行官兼董事会成员,以及医疗器械合同制造组织Spectralytics, Inc. 的总裁。他还在领先的 3D 打印公司 Stratasys 工作了四年,担任快速原型制作业务部门的副总裁兼总经理。Bartel 先生拥有哈特威克学院经济与管理双专业学士学位和圣托马斯大学欧普斯商学院工商管理硕士学位,主修商业、管理和市场营销。
Upon his appointment as CEO, Mr. Bartel commented, "Vantage has been on an exciting growth journey, and I'm grateful for the opportunity to serve as CEO. We have a talented team of 150+ medical device engineers with decades of industry expertise. Their dedication to partnering with medical device innovators from concept to realization is what makes Vantage stand apart and is key to our long term success."
在被任命为首席执行官后,巴特尔先生评论说:“Vantage一直处于激动人心的增长之旅中,我很感激有机会担任首席执行官。我们拥有一支由 150 多名医疗器械工程师组成的才华横溢的团队,他们拥有数十年的行业专业知识。从概念到实现,他们致力于与医疗器械创新者合作,这使Vantage脱颖而出,也是我们长期成功的关键。”
Vantage is backed by Boston-based private equity firm Ampersand Capital Partners ("Ampersand"). Trevor Wahlbrink, Partner at Ampersand added "We are thrilled to have Jim join the Vantage team given his exceptional leadership qualities and deep understanding of contract services companies serving the medical device industry. His experience, commitment to quality, and teamwork mentality will prove invaluable to Vantage's growth strategy."
Vantage由总部位于波士顿的私募股权公司Ampersand Capital Partners(“Ampersand”)提供支持。Ampersand合伙人Trevor Wahlbrink补充说:“我们很高兴Jim加入Vantage团队,因为他具有卓越的领导才能以及对服务于医疗器械行业的合同服务公司的深刻理解。他的经验、对质量的承诺和团队合作心态将证明对Vantage的增长战略非常宝贵。”
About Vantage MedTech
关于 Vantage MedTech
Vantage MedTech provides comprehensive design and manufacturing services, supporting the advancement of medical technologies from concept through to product realization. Partnering with the world's most innovative MedTech start-ups and large medical device companies, we offer feasibility support, product development and prototyping, clinical and commercial manufacturing, and after-market services to support every phase of the product life cycle. Our clients can leverage our proprietary Advantage Platforms, accelerating product development timelines. Our manufacturing approach is structured to serve the changing needs of our clients, supporting small-quantity clinical or First-in-Human builds and can scale to accommodate full launch quantities. Vantage MedTech has facilities in Moonachie, New Jersey and Lenexa, Kansas. Additional information is available at available at VantageMedTech.com and on LinkedIn.
Vantage MedTech 提供全面的设计和制造服务,支持医疗技术从概念到产品实现的发展。我们与世界上最具创新性的医疗科技初创企业和大型医疗器械公司合作,提供可行性支持、产品开发和原型设计、临床和商业制造以及售后服务,为产品生命周期的每个阶段提供支持。我们的客户可以利用我们专有的优势平台,加快产品开发进度。我们的制造方法旨在满足客户不断变化的需求,支持小批量临床或首次人体建造,并且可以扩展以适应全部发射量。Vantage MedTech在新泽西州的穆纳奇和堪萨斯州的莱内克萨设有工厂。更多信息可在VantageMedtech.com和LinkedIn上获得。
About Ampersand Capital Partners
关于安珀桑资本合伙人
Founded in 1988, Ampersand Capital Partners is a middle market private equity firm with $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit Ampersandcapital.com or follow us on LinkedIn.
Ampersand Capital Partners成立于1988年,是一家中间市场私募股权公司,管理着30亿美元的资产,专门用于医疗保健领域的增长导向型投资。Ampersand 在马萨诸塞州波士顿和荷兰阿姆斯特丹设有办事处,利用私募股权和运营经验的独特组合,与其投资组合公司管理团队一起创造价值并推动长期业绩。Ampersand 在公司的每个核心医疗保健领域帮助建立了众多市场领先的公司。欲了解更多信息,请访问 AmpersandCapital.com 或在 LinkedIn 上关注我们。
Contact:
Emily Shores
913-385-5700
[email protected]
联系人:
艾米丽海岸
913-385-5700
[电子邮件保护]
SOURCE Vantage MedTech
来源 Vantage MedTech
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧